BOUDREAUX GAIL purchased $1.0M of ELV
BOUDREAUX GAIL (President and CEO) purchased 2,725 shares of Elevance Health, Inc. (ELV) at an average of $367.79 ($366.41–$368.25, $1.00M total) across 2 trades on 2026-07-17.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s open-market purchase details: 2,725 shares across two trades at $366.41 to $368.25, totaling about $1.0M.
Market read
Traders may treat the disclosure as a small sentiment input, but it is not a substitute for earnings, guidance, or regulatory news.
What to watch
The filing notes no pre-arranged 10b5-1 plan, but it still does not disclose the insider’s motivation, timing constraints, or whether other transactions occurred around the same period.
Background
This is an SEC Form 4 insider transaction for Elevance Health, Inc. (ELV) filed on 2026-07-17.
Ticker impact
Elevance Health CEO Boudreaux Gail bought about $1.0M of ELV shares in an open-market Form 4 on 2026-07-17.
Likely limited near-term impact; any effect is small and short-lived versus earnings or guidance catalysts.
The article is a primary Form 4 disclosure with transaction size and price range, but it provides no new company performance, outlook, or regulatory/contract event.
Market effects
Minimal; insider buying at one managed-care name rarely resets sector expectations without accompanying guidance or regulatory developments.
None indicated.
None indicated.
Counterpoint
Insider open-market purchases can be routine (liquidity planning, diversification, or pre-scheduled behavior) and may not imply undervaluation.
Key entities
- issuerElevance Health, Inc.
Subject of the Form 4 insider transaction; CEO purchased shares on 2026-07-17.
- insiderBOUDREAUX GAIL
President and CEO who executed the open-market purchase.
%252FElevance%252520Health%252520world%252520headquarters%252520By%252520jetcityimage.jpeg&w=3840&q=75)
